מחקר מגלה: טיפול ב-SIL204 עשוי לסייע למערכת החיסון לתקוף גידולים המונעים על ידי KRAS - בלעדי

הערכה

SIL204, a treatment that may enable the immune system to attack KRAS-driven tumors, has advanced to Phase 2/3 clinical evaluation. The first trial is underway at Tel Aviv Sourasky Medical Center. This development signals a potential new therapeutic avenue for cancers driven by KRAS mutations, which have historically been difficult to target.